Alzheimer’s disease: have drug developers been on the wrong track for decades?

Description

US drug giant Eli Lilly recently announced yet another failure in the quest to develop a treatment for Alzheimer’s disease in November last year. Its drug candidate solanezumab, an antibody which attacks amyloid-β protein aggregates, had crashed and burned in Phase III clinical trials, failing to significantly slow down cognitive decline in patients with mild dementia.